Pharma News

Revenue for Inotersen sodium is expected to have a CAGR of -30.16% through 2030

Inotersen sodium is a Antisense Oligonucleotide owned by Akcea Therapeutics, and is involved in 9 clinical trials, of which 5 were completed, and 4 are ongoing.

ISIS-TTRRx is a transthyretin (TTR) protein inhibitor. Normal and mutant forms of TTR progressively accumulate in tissues in transthyretin amyloidosis hence impairing the tissue function. The drug candidate blocks the production of both normal and mutant TTR due to which the supply of TTR protein is reduced, which leads to the prevention of the formation of TTR amyloid deposits in the tissues.

The revenue for Inotersen sodium is expected to reach a total of $249m through 2030. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Inotersen sodium NPV Report.

Inotersen sodium was originated by Ionis Pharmaceuticals and is currently owned by Akcea Therapeutics. PTC Therapeutics, Ionis Pharmaceuticals and Swedish Orphan Biovitrum are the other companies associated in development or marketing of Inotersen sodium.

Inotersen sodium Overview

Inotersen sodium (Tegsedi) is a methoxyethyl phosphorothioate antisense oligonucleotide. It is formulated as solution for subcutaneous route of administration. Tegsedi is indicated for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR) and also indicated for the treatment of stage 1 or 2 polyneuropathy in adult patients with hereditary transthyretin-associated amyloidosis (PAF-TTR) to slow disease progression and improve quality of life

It is under development for the treatment of amyloid cardiomyopathy and familial amyloid polyneuropathy (FAP/hereditary transthyretin amyloidosis). It is administered through subcutaneous route. It was under development for familial amyloid neuropathies.

Swedish Orphan Biovitrum Overview

Swedish Orphan Biovitrum (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS) and Hemophilia A. Sobi also manufactures and markets specialty products for rare diseases for partner companies. The company has operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden.

The company reported revenues of (Swedish Krona) SEK15,529 million for the fiscal year ended December 2021 (FY2021), an increase of 1.8% over FY2020. In FY2021, the company’s operating margin was 24%, compared to an operating margin of 31.6% in FY2020. In FY2021, the company recorded a net margin of 17.3%, compared to a net margin of 21.3% in FY2020.
The company reported revenues of SEK3,999 million for the third quarter ended September 2022, an increase of 3.2% over the previous quarter.

Quick View – Inotersen sodium

Report Segments
Drug Name
Administration Pathway
Therapeutic Areas
Key Companies
Highest Development Stage

Source link
#Revenue #Inotersen #sodium #expected #CAGR

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *